Serina Therapeutics, Inc.

What they do

The company develops drug product candidates designed to improve the efficacy and safety profiles of small molecules, RNA-based therapeutics and antibody-drug conjugates using its proprietary POZ technology, a synthetic water-soluble low-viscosity poly(2-oxazoline) polymer engineered to control drug loading and release rate. Its therapeutic agents are typically well-understood, marketed drugs limited by pharmacokinetic profiles such as toxicity, side effects and short half-life. Serina is headquartered in Huntsville, Alabama and is a smaller reporting company listed on NYSE American under the symbol SER.

Revenue drivers

• No product revenue — The company has no approved products and does not expect product sales unless and until it completes development and obtains regulatory approval for a product candidate.
• Historical collaboration and other revenue — Annual revenue has been minimal and irregular: $56,000 in 2024 and $130,000 in 2025, with no revenue reported in the quarters ended September 30, 2025, December 31, 2025, or June 30, 2026.
• Grant/other income — The 2023 revenue level of $3.2 million is not explained in the provided excerpts and was not repeated in later years.

Recent performance

For the three months ended June 30, 2026, operating expenses were $6.8 million versus $5.7 million in 2025, with R&D of $3.8 million and G&A of $3.0 million. The net loss attributable to common shareholders was $8.9 million, or $(0.55) per basic and diluted share, compared to a $6.6 million net loss, or $(0.66) per share, a year earlier. Other income was $0.4 million, driven by non-cash gains on liability-classified warrants and settlement of a tranche liability tied to the March 2026 PIPE. Revenue was $0.00 in the quarter. Six-month operating loss was $13.1 million in 2026 versus $11.4 million in 2025, and accumulated deficit reached $76.8 million as of June 30, 2026.

Strategy

The near-term priority is disciplined clinical execution on SER-252, the lead candidate being studied in a Phase 1b registrational study in advanced Parkinson's disease. Serina completed enrollment and dosing of all eight patients in Cohort 1 in July 2026, ahead of prior guidance, and the independent Safety Monitoring Committee will review Cohort 1 safety to inform the next dose-escalation decision. In June 2026 the company entered a development partnership with Gannet BioChem to support process development, scale-up and manufacturing for SER-252. Management also states it will advance other product candidates and preclinical programs, invest further in the pipeline, protect intellectual property, and add headcount to support development.

Risks

• Going concern — The company states that losses from operations, negative operating cash flows, its accumulated deficit, and capital needed within one year raise substantial doubt about its ability to continue as a going concern.
• Need for additional financing — Serina expects substantial future expenditures for development and will require additional financing; it has historically funded operations through equity, private placements, convertible preferred stock, convertible notes, warrant exercises and an ATM program.
• Clinical and regulatory risk — SER-252 is in a Phase 1b registrational study, with top-line data from the single-ascending-dose arm targeted for the first half of 2027, and no product candidate has received regulatory approval.
• No product revenue — The company has not had any products approved for sale and does not expect product sales unless and until development succeeds and regulatory approval is obtained.

Outlook

Management targets top-line data from the single-ascending-dose arm of the SER-252 Phase 1b study in the first half of 2027 and expects a protocol-defined safety review and dose-escalation decision following Cohort 1. The company expects research and development, general and administrative expenses, and capital expenditures to continue to increase. It states that its near-term priority remains disciplined clinical execution to generate data on whether SER-252 can deliver a differentiated profile in advanced Parkinson's disease.